Drug Profile
Research programme: chemokine antagonists - Icogenex
Alternative Names: Chemokine antagonists research programme - IcogenexLatest Information Update: 10 Oct 2012
Price :
$50
*
At a glance
- Originator Icogenex Corporation
- Class Peptides
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 10 Oct 2012 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 23 Feb 2004 Icogen Corporation is now called Icogenex Corporation
- 13 Feb 2003 Preclinical trials in Inflammation in USA (unspecified route)